The Evolving Landscape of Impella® Use in the United States Among Patients Undergoing Percutaneous Coronary Intervention with Mechanical Circulatory Support.
Background: Impella® was approved for mechanical circulatory support (MCS) in 2008, but large-scale, real-world data on its use are lacking. Our objective was to describe trends and variations in Impella® use, clinical outcomes and costs across US hospitals in percutaneous coronary intervention (PCI) patients treated with MCS (Impella® or intra-aortic balloon pump (IABP)). Methods: From the Premier Healthcare Database, we analyzed 48,306 patients undergoing PCI with MCS at 432 hospitals between 1/2004-12/2016. Association analyses were performed at three levels: time-period, hospitals and patients. Hierarchical models with propensity adjustment were used for association analyses. We examined trends and variations in the proportion of Impella® use, and associated clinical outcomes (in-hospital mortality, bleeding requiring transfusion, acute kidney injury (AKI), stroke, length of stay (LOS) and hospital costs). Results: Among PCI patients treated with MCS, 4,782 (9.9%) received Impella®; its use increased over time, reaching 31.9% of MCS in 2016. There was wide variation in Impella® use across hospitals (> 5-fold variation). Specifically, among Impella® patients, there was wide variation in outcomes of bleeding (> 2.5-fold variation), and death, AKI and stroke (all ~1.5-fold variation). Adverse outcomes and costs were higher in the Impella®-era (years 2008-2016) vs. the pre-Impella® era (years 2004-2007). Hospitals with higher Impella® use had higher rates of adverse outcomes and costs. After adjustment for the propensity score, and accounting for clustering of patients by hospitals, Impella® use was associated with death: OR 1.24 (95%CI 1.13-1.36); bleeding: OR 1.10 (95%CI 1.00-1.21); and stroke: OR 1.34 (95%CI 1.18-1.53), although a similar, non-significant result was observed for AKI: OR 1.08 (95%CI 1.00-1.17). Conclusions: Impella® use is rapidly increasing among PCI patients treated with MCS, with marked variability in its use and associated outcomes. Although unmeasured confounding cannot be ruled out, when analyzed by time-periods, or at the hospital-level or the patient-level, Impella® use was associated with higher rates of adverse events and costs. More data are needed to define the appropriate role of MCS in patients undergoing PCI.